Thermo Fisher in talks to buy Patheon: Bloomberg

Go back to Thermo Fisher in talks to buy Patheon: Bloomberg

Jefferies Remains Sidelined on Thermo Fisher Scientific (TMO) Following Announced Acquisition of PTHN

May 16, 2017 7:25 AM EDT

Jefferies reiterated a Hold rating and $175.00 price target on Thermo Fisher Scientific (NYSE: TMO) following the company's announced move to acquire PTHN. TMO is paying $35/sh in cash and assuming ~$2B of net debt, implying an EV of $7.2B.

The deal marks... More

Thermo Fisher Scientific (TMO) to Acquire Patheon (PTHN) for $7.2B

May 15, 2017 7:02 AM EDT

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2.0 billion of net... More

Thermo Fisher Scientific (TMO) Said in Talks to Buy Patheon (PTHN) - Bloomberg

May 15, 2017 6:22 AM EDT

Thermo Fisher Scientific (NYSE: TMO) is in talks to acquire Patheon N.V. (NYSE: PTHN), according to Bloomberg, citing people with knowledge of the matter. An agreement could be reached as early as this week.

... More